MediciNova (MNOV) Completes LPLV in Double-Blind Phase of COMBAT-ALS

MediciNova completed the last patient, last visit in the double-blind portion of its Phase 2b/3 COMBAT-ALS trial of MN-166 and expects topline results by end-2026. Full study LPLV is expected in March 2027.Material DetailsContext by AI AnalystThis is a late-stage operational milestone that confirms…